{"name":"Ajinomoto Bio-Pharma Services","slug":"ajinomoto-bio","ticker":"2802.T","exchange":"Tokyo Stock Exchange (parent: Ajinomoto Co.)","domain":"ajibio-pharma.com","description":"Ajinomoto Co., Inc. engages in the seasonings and foods, frozen foods, and healthcare and other businesses in Japan and internationally. The Seasonings and Foods segment offers sauces and seasoning products under the AJI-NO-MOTO, HON-DASHI, Cook Do, Ajinomoto KK Consommé, Pure Select Mayonnaise, Ros Dee, Masako, Aji-ngon, Sazón, Sajiku, and CRISPY FRY names. This segment also provides instant noodles under the Knorr Cup Soup and YumYum names; coffee beverages under the Birdy and Blendy brands; powdered drink under the Birdy 3in1 name; MAXIM brand products; A Little Luxury Coffee Shop brand products and various gifts, office drinks, cup vending machines, and tea dispensers, etc. The Frozen Foods segment offers Gyoza dumplings, rice dishes, noodles, sweets, shumai, processed chicken, and other products. The Healthcare and Other segment provides amino acids for applications in various industries, such as pharmaceuticals and foods; contract development and manufacturing services for pharma","hq":"San Diego, CA, USA / Tokyo, Japan","founded":0,"employees":"~34,860","ceo":"James Quigley","sector":"CDMO / Oligonucleotide & ADC Specialist","stockPrice":5542,"stockChange":59,"stockChangePercent":1.08,"marketCap":"$33.6B","metrics":{"revenue":10012068262.520935,"revenueGrowth":10.5,"grossMargin":37.7,"rdSpend":0,"netIncome":851398053.7997091,"cash":674499464.975496,"dividendYield":0.91,"peRatio":40.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Lynparza patent cliff ($1.4B at risk)","drug":"Lynparza","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Keytruda patent cliff ($14.5B at risk)","drug":"Keytruda","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-15","type":"earnings","headline":"Ajinomoto Bio-Pharma Services Reports Strong Financial Results for Q4 2022","summary":"Ajinomoto Bio-Pharma Services reported strong financial results for Q4 2022, with revenue growth and increased profitability.","drugName":"","sentiment":"positive"},{"date":"2022-08-25","type":"deal","headline":"Ajinomoto Bio-Pharma Services and Fujifilm Diosynth Biotechnologies Announce Collaboration","summary":"Ajinomoto Bio-Pharma Services and Fujifilm Diosynth Biotechnologies have entered into a collaboration to provide integrated services for the development and manufacturing of biologics.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPVGc1Wm9hT1N0MnEwSTlhSm5zNHNVekV3Ujd4LV80TzlobzE0LTNTSzFsRE9uYXJiUGhwaTB3Vi1zaElEZEtsbldvYkZlaVpLX0hXSHBJUmVjbEFQemJPZW5hQmp1V19ySHktOVRVYzlEaWtSakxkQ3VqT2dZRUFnZ0hCOGZ5aEhqaU5nOUZB?oc=5","date":"2025-10-25","type":"pipeline","source":"Yahoo Finance","summary":"Ajinomoto (TSE:2802): Revisiting Valuation After Strong Shareholder Returns and Persistent Growth Trends - Yahoo Finance","headline":"Ajinomoto (TSE:2802): Revisiting Valuation After Strong Shareholder Returns and Persistent Growth Trends","sentiment":"neutral"}],"patents":[{"drugName":"Lynparza","drugSlug":"olaparib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Keytruda","drugSlug":"pembrolizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":14500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Lonza Group AG","Catalent, Inc.","Thermo Fisher Scientific Inc."],"therapeuticFocus":["Oncology","Rare Diseases"],"financials":{"source":"yahoo_finance","revenue":9675978661.665201,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":9675978661.665201},{"period":"2024-03-31","value":9098633728.6627},{"period":"2023-03-31","value":8592150655.5455},{"period":"2022-03-31","value":7266169675.829}],"grossProfit":3481859344.9788003,"grossProfitHistory":[{"period":"2025-03-31","value":3481859344.9788003},{"period":"2024-03-31","value":3233308637.2216},{"period":"2023-03-31","value":2973726263.3479004},{"period":"2022-03-31","value":2692466191.4149003}],"rdSpend":195478594.8357,"rdSpendHistory":[{"period":"2025-03-31","value":195478594.8357},{"period":"2024-03-31","value":181854961.3222},{"period":"2023-03-31","value":163527855.2639},{"period":"2022-03-31","value":157047936.7714}],"sgaSpend":2319203920.6318,"operatingIncome":680587419.7352,"operatingIncomeHistory":[{"period":"2025-03-31","value":680587419.7352},{"period":"2024-03-31","value":897408653.4301001},{"period":"2023-03-31","value":914155291.5634},{"period":"2022-03-31","value":781301157.7879001}],"netIncome":444250568.1024,"netIncomeHistory":[{"period":"2025-03-31","value":444250568.1024},{"period":"2024-03-31","value":550767784.3757},{"period":"2023-03-31","value":594666861.4605},{"period":"2022-03-31","value":478723734.4825}],"eps":34.885,"epsHistory":[{"period":"2025-03-31","value":34.885},{"period":"2024-03-31","value":83.7},{"period":"2023-03-31","value":87.98},{"period":"2022-03-31","value":69.71}],"cash":1041692731.2392001,"cashHistory":[{"period":"2025-03-31","value":1041692731.2392001},{"period":"2024-03-31","value":1084434905.8029},{"period":"2023-03-31","value":839399158.7109001},{"period":"2022-03-31","value":957472756.4518001}],"totalAssets":10880769360.8927,"totalLiabilities":5739361797.818601,"totalDebt":2878683244.2101,"equity":4721199073.046801,"operatingCashflow":1326948226.0866,"operatingCashflowHistory":[{"period":"2025-03-31","value":1326948226.0866},{"period":"2024-03-31","value":1062542264.1058},{"period":"2023-03-31","value":743704986.7880001},{"period":"2022-03-31","value":920312794.5992}],"capex":-601146779.9530001,"capexHistory":[{"period":"2025-03-31","value":-601146779.9530001},{"period":"2024-03-31","value":-455313843.5774},{"period":"2023-03-31","value":-461787440.19820005},{"period":"2022-03-31","value":-510295161.7523}],"freeCashflow":725801446.1336,"dividendsPaid":-247412770.8512,"buybacks":-573362153.8315,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":32.62,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5542,"previousClose":5483,"fiftyTwoWeekHigh":5739,"fiftyTwoWeekLow":3242,"fiftyTwoWeekRange":"3242.0 - 5739.0","fiftyDayAverage":4668.94,"twoHundredDayAverage":4108.81,"beta":0.41,"enterpriseValue":36033524507.691666,"forwardPE":23.9,"priceToBook":6.89,"priceToSales":3.35,"enterpriseToRevenue":3.6,"enterpriseToEbitda":20.34,"pegRatio":1.57,"ebitda":1771489668.2599647,"ebitdaMargin":17.7,"freeCashflow":623760139.7044872,"operatingCashflow":1513146346.039283,"totalDebt":2663752223.0453143,"debtToEquity":49.9,"currentRatio":1.57,"returnOnAssets":6.8,"returnOnEquity":17.5,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":14,"targetMeanPrice":5092.86,"targetHighPrice":6200,"targetLowPrice":3650,"dividendRate":50,"payoutRatio":0.35,"fiveYearAvgDividendYield":1.26,"exDividendDate":1790640000,"insiderHeldPercent":0.3,"institutionHeldPercent":61.1,"sharesOutstanding":958444777,"floatShares":952004028,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":138.17,"epsForward":232.13,"revenuePerShare":1627.05,"bookValue":804.24,"officers":[{"age":58,"name":"Mr. Shigeo  Nakamura","title":"President, CEO, Representative Executive Officer & Director"},{"age":57,"name":"Michael  Lish","title":"Executive Officer & Deputy GM of Bio & Fine Chemicals Division"},{"age":null,"name":"Mr. Saburosuke  Suzuki II","title":"Founder"},{"age":null,"name":"Hirokazu  Yoshimoto","title":"Senior Manager of Global Finance Department"},{"age":null,"name":"Ms. Naralice  Fuzinelli","title":"Global Technology Manager"},{"age":null,"name":"Yosuke  Kakihara","title":"Executive Officer of Legal & Compliance"},{"age":60,"name":"Hiroshi  Kaho","title":"Representative Executive Officer, Executive VP & Chief Human Resources Officer"},{"age":62,"name":"Mr. Takayuki  Tahara","title":"Executive Officer, VP & Deputy GM of Food Products Div, Supervision of Food Products Sales"}],"industry":"Packaged Foods","irWebsite":"http://www.ajinomoto.com/en/ir/","website":"https://www.ajinomoto.co.jp","phone":"81 3 5250 8111"}}